Aeglea BioTherapeutics Receives FDA Rare Pediatric Disease Designation for ACN00177 for the Treatment of Homocystinuria ...Middle East

AUSTIN, Texas, Dec. 1, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high burden diseases, today announced the U.S. Food and Drug...

Read More Details
Finally We wish PressBee provided you with enough information of ( Aeglea BioTherapeutics Receives FDA Rare Pediatric Disease Designation for ACN00177 for the Treatment of Homocystinuria )

Also on site :

• Tears and Shock: First Islander Sent Home on ‘Love Island USA’ Season 7
• 'Hamilton’ Original Cast Reunites at 2025 Tony Awards & Fans Are Saying the Same Thing
• Today’s NYT ‘Strands’ Hints, Spangram and Answers for Monday, June 9